Summary
Definition
History and exam
Key diagnostic factors
- presence of risk factors
- cough
- dyspnoea
- haemoptysis
- chest and/or shoulder pain
- weight loss
Other diagnostic factors
- male sex
- fatigue
- pulmonary examination abnormalities
- hoarseness
- confusion
- personality changes
- nausea and vomiting
- headache
- dysphagia
- bone pain and/or fractures
- weakness, paraesthesias and/or pain in C8/T1 distribution
- seizures
- cervical or supraclavicular adenopathy
- Horner's syndrome
- facial swelling
- dilated neck or chest/abdominal wall veins
- finger clubbing
- hypertrophic pulmonary osteoarthropathy
Risk factors
- cigarette smoking
- environmental tobacco exposure
- chronic obstructive pulmonary disease
- family history
- radon gas exposure
- asbestos exposure
- older age
Diagnostic investigations
1st investigations to order
- chest x-ray
- contrast-enhanced CT scan of lower neck, thorax, and upper abdomen
Investigations to consider
- sputum cytology
- bronchoscopy
- biopsy
- diagnostic thoracentesis and/or pleural biopsy
- sampling of the mediastinal lymph nodes: mediastinoscopy and endobronchial ultrasound
- video-assisted thoracoscopic surgery (VATS)
- thoracoscopy
- MRI or CT of brain
- MRI of thoracic inlet
- PET-CT
- bone scan
- contrast-enhanced CT liver and adrenals
- pulmonary function tests (PFT)
- FBC
- LFTs
- serum calcium
- electrolytes and renal function
- electrocardiogram and echocardiogram
- epidermal growth factor receptor (EGFR) mutation testing
- anaplastic lymphoma kinase (ALK) testing
- ROS1 testing
- programmed death-ligand 1 (PD-L1) testing
- BRAF testing
- NTRK fusion testing
Treatment algorithm
stage I and II
stage IIIA
stage IIIB and IIIC
stage III with tumours too extensive for combination chemoradiotherapy or stage IV and suitable for immunotherapy or targeted therapy
stage III with tumours too extensive for combination chemoradiotherapy or stage IV and unsuitable for immunotherapy or targeted therapy (ECOG performance 0-2)
stage III with tumours too extensive for combination chemoradiotherapy or stage IV and unsuitable for immunotherapy or targeted therapy (ECOG performance 3-4)
Contributors
Authors
Professor David R. Baldwin, MD, FRCP
Consultant Respiratory Physician
Nottingham University Hospitals
Honorary Professor of Medicine
University of Nottingham
Respiratory Medicine Unit
David Evans Research Centre
City Hospital Campus
Nottingham
UK
Disclosures
DRB declares that he has no competing interests.
Sanjay Popat, FRCP, PhD
Consultant Medical Oncologist
Department of Medicine
Royal Marsden Hospital
London
UK
Disclosures
SP has been paid and acted as a consultant to BMS, Eli Lilly, Roche, Takeda, AstraZeneca, Chugai, Novartis, Pfizer, MSD, EMD Serono, Guardant Health, AbbVie, Boehringer Ingelheim, and Tesaro. SP has received research grants from Pierre Fabre, Otsuka, and Boehringer Ingelheim. SP has received assistance for travel from Boehringer Ingelheim, MSD, and Pfizer.
Acknowledgements
Professor David R. Baldwin and Dr Sanjay Popat would like to gratefully acknowledge Dr Mick Peake, Dr Chris Kelsey, and Dr Lawrence Marks, previous contributors to this topic.
Disclosures
MP has received lecture fees from AstraZeneca Pharmaceuticals, Lilly Oncology Ltd, Pierre-Fabre, GSK Ltd, and Roche Pharmaceuticals Ltd. MP has also received educational grants to attend scientific conferences from Roche Pharmaceuticals Ltd and Boehringer Ingelheim Ltd. CK and LM declare that they have no competing interests.
Peer reviewers
Alan Neville, MD
Professor
Assistant Dean
Undergraduate Program
McMaster University
Hamilton
Ontario
Canada
Disclosures
AN declares that he has no competing interests.
James Huang, MD
Assistant Attending Surgeon
Thoracic Service
Memorial Sloan Kettering Cancer Center
New York
NY
Disclosures
JH declares that he has no competing interests.
Siow Ming Lee, PhD, FRCP
Consultant Medical Oncologist
University College Hospital
London
UK
Disclosures
SML declares that he has no competing interests.
Differentials
- Small cell lung cancer
- Metastatic cancer
- Pneumonia/bronchitis
More DifferentialsGuidelines
- Suspected cancer: recognition and referral
- Therapy for stage IV non-small-cell lung cancer without driver alterations
More GuidelinesPatient leaflets
Lung cancer (non-small-cell)
Lung cancer: questions to ask your doctor
More Patient leafletsVideos
Insertion of intercostal drain Seldinger technique animated demonstration
Venepuncture and phlebotomy animated demonstration
More videosLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer